Journal of Acquired Immune Deficiency Syndromes ; JAIDS 2003: Vol 32 Index

15 Pages·2003·3.4 MB·English

JAIDS Journal of Acquired Immune Deficiency Syndromes
32:576-579 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia
Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003
Author Index
Aarnoutse RE, 287 Berria MI, 441 CASCADE Collaboration, 303
Aberg JA, 153 Betha G, 345 Caseiro M, 551
Abrams E, 192 Beyrer C, 311 Castelli F, 259, 268
Acosta EP, 506 Bhattacharya SK, 115 Castro E, 338
Adu-Oppong A, 399 Biggar RJ, 527 Catania JA, 417
Adult/Adolescent Spectrum of HIV Biglione MM, 441 Cazali N, 112
Disease Group, 499 Binson D, 417 Celentano DD, 86, 229
Aga E, 281 Birch C, 57 Celum CL, 318
Agbaria R, 477 Birkhead GS, 292 Chadapaud S, 462
Alarcon A, 240 Birx DL, 9, 215 Chapman V, 506
Alix J, $39 Blanche S, 112 Cheku B, 292
Alkaer G, 112 Blattner WA, 94 Chen JL, 182
Alves K, 551 Blaxhult A, 452 Chéne G, 38
Ananworanich J, 570 Blijenberg BG, 135 Cheng J, 245
Anastos K, 298 Blok WL, 135 Chernoff M, 281
Anderson DM, 469 Blumberg SJ, 77 Chiesi A, 452
Anderson RN, 62 Bomfim A, 435 Chironi G, 490
Angarano G, 268 Bonu S, 388 Christophersen B, 354
Antelman G, 560 Bosch RJ, 281 Chuenyam T, 570
Anthony JC, 429 Brahmbhatt H, 394 Cleghorn FR, 94
APROCO Study Group, 38 Brambilla P, 482 Clevenbergh P, 345
Arakaki R, 281 Branson BM, 318 Clouse KA, 362
Archibald CP, S24 Bressan C, 435 Cogny A, 490
Arduino RC, 399 Bricalli D, 482 Cohen CR, 223
Ariyoshi K, 157 Brookmeyer R, 311 Cohen MS, 131
Armon C, 48 Brown T, S12 Colby DJ, 80
Aronson N, 9 Bulterys M, 192 Colebunders R, 452
Arruda JS, 388 Burchell AN, 534 Coletti AS, 161
Arya J, 469 Burgard M, 112 Combadiére C, 335
Asensi V, 348 Burger D, 375 Connick E, 469
Astemborski JA, 429 Burger DM, 135, 287 Constantine NT, 94
Aukrust P, 354 Busch MP, 551 Contopoulos-Ioannidis DG, 70
Ayuka F, 223 Contos MJ, 30
Coombs R, 170
Bai J, 245 Cafarella T, 94 Coombs RW, 281
Bai Y, 406 Callea F, 259 Cooper D, 57
Balzarini J, 477 Calzavara LM, 534 Cooper DA, 375, 542
Barak J, 477 Cao C, 406 Cossarizza A, 370
Barcan LA, 104 Cao Y, 124 Coutinho RA, 514
Bardeguez AD, 170 Cardiello PG, 375 Critchlow CW, 318
Barroso PF, 435 Carosi G, 259, 268 Crowe S, 57
Bartholomew C, 94 Carpenter CCJ, 203 Cunningham B, 170
Bastos FI, 338 Carr A, 542
Bayer R, 182 Carr JK, 215
Beccio S, 482 Carrieri P, 38 Dalessandro M, 464
Beer BE, 362 Carton JA, 348 Danoff A, 298
Belloso WH, 104 Casado L, 348 Das P, 115
Benning L, 298 Casari S, 259 de Groot R, 135
Berchich L, 259 Casau NC, 494 Debré P, 335
JAIDS Journal of Acquired Immune Deficiency Syndromes
32:576-579 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia
Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003
Author Index
Aarnoutse RE, 287 Berria MI, 441 CASCADE Collaboration, 303
Aberg JA, 153 Betha G, 345 Caseiro M, 551
Abrams E, 192 Beyrer C, 311 Castelli F, 259, 268
Acosta EP, 506 Bhattacharya SK, 115 Castro E, 338
Adu-Oppong A, 399 Biggar RJ, 527 Catania JA, 417
Adult/Adolescent Spectrum of HIV Biglione MM, 441 Cazali N, 112
Disease Group, 499 Binson D, 417 Celentano DD, 86, 229
Aga E, 281 Birch C, 57 Celum CL, 318
Agbaria R, 477 Birkhead GS, 292 Chadapaud S, 462
Alarcon A, 240 Birx DL, 9, 215 Chapman V, 506
Alix J, $39 Blanche S, 112 Cheku B, 292
Alkaer G, 112 Blattner WA, 94 Chen JL, 182
Alves K, 551 Blaxhult A, 452 Chéne G, 38
Ananworanich J, 570 Blijenberg BG, 135 Cheng J, 245
Anastos K, 298 Blok WL, 135 Chernoff M, 281
Anderson DM, 469 Blumberg SJ, 77 Chiesi A, 452
Anderson RN, 62 Bomfim A, 435 Chironi G, 490
Angarano G, 268 Bonu S, 388 Christophersen B, 354
Antelman G, 560 Bosch RJ, 281 Chuenyam T, 570
Anthony JC, 429 Brahmbhatt H, 394 Cleghorn FR, 94
APROCO Study Group, 38 Brambilla P, 482 Clevenbergh P, 345
Arakaki R, 281 Branson BM, 318 Clouse KA, 362
Archibald CP, S24 Bressan C, 435 Cogny A, 490
Arduino RC, 399 Bricalli D, 482 Cohen CR, 223
Ariyoshi K, 157 Brookmeyer R, 311 Cohen MS, 131
Armon C, 48 Brown T, S12 Colby DJ, 80
Aronson N, 9 Bulterys M, 192 Colebunders R, 452
Arruda JS, 388 Burchell AN, 534 Coletti AS, 161
Arya J, 469 Burgard M, 112 Combadiére C, 335
Asensi V, 348 Burger D, 375 Connick E, 469
Astemborski JA, 429 Burger DM, 135, 287 Constantine NT, 94
Aukrust P, 354 Busch MP, 551 Contopoulos-Ioannidis DG, 70
Ayuka F, 223 Contos MJ, 30
Coombs R, 170
Bai J, 245 Cafarella T, 94 Coombs RW, 281
Bai Y, 406 Callea F, 259 Cooper D, 57
Balzarini J, 477 Calzavara LM, 534 Cooper DA, 375, 542
Barak J, 477 Cao C, 406 Cossarizza A, 370
Barcan LA, 104 Cao Y, 124 Coutinho RA, 514
Bardeguez AD, 170 Cardiello PG, 375 Critchlow CW, 318
Barroso PF, 435 Carosi G, 259, 268 Crowe S, 57
Bartholomew C, 94 Carpenter CCJ, 203 Cunningham B, 170
Bastos FI, 338 Carr A, 542
Bayer R, 182 Carr JK, 215
Beccio S, 482 Carrieri P, 38 Dalessandro M, 464
Beer BE, 362 Carton JA, 348 Danoff A, 298
Belloso WH, 104 Casado L, 348 Das P, 115
Benning L, 298 Casari S, 259 de Groot R, 135
Berchich L, 259 Casau NC, 494 Debré P, 335
AUTHOR INDEX
DeHovitz J, 210 Geskus RB, 514 Ichikawa S, S55
Deibis L, 338 Gianotti N, 268 Imam G, 394
Delaney KM, 48 Gilleece YC, 238 Infuso A, $39
Di Iorio A, 464 Giordano TP, 399 International Collaboration on HIV
Di Sora F, 424 Gisselquist D, 349 Optimism, 545
Diaz RS, 551 Glesby MJ, 494 Ioannidis JPA, 70
Dickey WC, 77 Goedert JJ, 70, 527 Ivalo SA, 104
Dieleman JP, 135 Goldbaum GM, 318 Izumo S, 328
Dietrich M, 452 Golden MR, 196
Dos Santos Moreira A, 338 Goldenberg RL, 506
Jack N, 94
Downs AM, S39 Goldwasser P, 210
Jacobson JM, 281
Droste JAH, 287 Golub ET, 429
Jesudason MV, 573
Duran S, 38 Go6mez-Vera J, 240
Jin L, 124
Dworkin MS, 499 Gonzalez de Salmen B, 338 Jiraphongsa C, S63
Gonzalez-Lahoz J, 465
Johnson AM, 452
Eboshida A, S55 Goudsmit J, 514 Johnson RP, 245
Echeverria G, 338 Graviss EA, 399 Jones JL, 499
Edwards J, 94 Gray RH, 446 Jones T, 170
Eiraku N, 328 Greenblatt RM, 298 Juethner SN, 153
El Habib R, 9 Grigolato P, 259 Justman JE, 298
Ellen JM, 388 Grimes J, 9
Emery S, 57 Grimm TA, 362
Engels EA, 527 Gross M, 161 Kalayjian R, 281
Ensoli F, 464 Guimaraes ML, 338 Kaldor J, S18
Erdem G, 370 Gulick RM, 494 Kamakura M, S1, S55
Escaut L, 490 Gupta AK, 115 Kamemoto L, 370
Escobar M, 534 Gupta P, 435 Kannangai R, 573
Gyssens IC, 135 Katlama C, 38, 452
Kelly RJ, 446
Falasca K, 464
Kerr T, 2
Falcao ME, 551 Hales G, 57
Kihara M, S1, S55
Fantry LE, 243 Hamers FF, $39
Kim JH, 9
Faure S, 335 Hamouda O, S49
Kirk O, 452
Favret M, 259 Handsfield HH, 196
Klein D, 143
Fawzi WW, 560 Hanson DL, 499
Klein RS, 203
Feldman JG, 210 Harrison LH, 435
Koblin BA, 161
Feldman MD, S1, S55 Hashimoto S, S55
Kombila M, 345
Feliu E, 347 Hayes R, 351
Koopmans PP, 287
Feng T, 131 Hazen R, 255
Kreisel K, 94
Feng T-J, 124 Heagerty P, 161
Kubota R, 328
Fleming PL, S68 Heggelund L, 354
Kumwenda-Phiri R, 506
Folkvord JM, 469 Hekster YA, 287
Kurth A, 318
Fowler MG, 170 Henderson LA, 229
Fox L, 281 Hill A, 375
Foy H, S63 Hill C, 9 Labrique A, 311
Francois C, 38 Hirsch VM, 362 Lacarelle B, 462
Frenkel LM, 170 Hirschel B, 542 Ladisa N, 268
Fr¢land SS, 354 Hittinger G, 462 Lafeuillade A, 462
Fuller CM, 86 HIV Outpatient Study Investigators, 48 Lahart CJ, 399
Furukawa Y, 328 Hoffman IF, 131 Lang J-M, 38
Hogg RS, 2, 522 Lange JM, 375
Galich AM, 104 Holman S, 210 Lanier ER, 255
Gallagher BK, 292 Holmberg SD, 48, 203 Latkin CA, 86
Galli C, 424 Holmes KK, 196 Law M, 57
Galvin SR, 131 Hong W-G, 124 Lazzari S, S3
Gandia J, 170 Hoover DR, 429 Lazzarin A, 268
Garcia-Samaniego J, 465 Hopkins SG, 196 Lederman MM, 281
Gardner LI, 203 Hou J, 124 Lee F, 192
Gariepy J, 490 Hoy J, 57 Lei Z-Y, 124
Gazzard BG, 238 Hu L-P, 124 Leport C, 38
Geduld J, S24 Huang S, 170 Levenson J, 490
Genin E, 335 Hugonnet S, 351 Levine A, 298
Gerschenson M, 370 Hurley LB, 143 Li K, 2
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
578 AUTHOR INDEX
Lichtenstein KA, 48 Nakagawa M, 328 Quesenberry CP Jr, 143
Liu M-X, 124 Nakashima AK, S68 Quirés RE, 104
Liu Z-D, 124 Narayan S, 572 Quiros-Roldan E, 259, 268
Lloyd RM Jr, 292 Navarro J-T, 347
Lo Caputo S, 268 Nelson MR, 238 Rabidas VN, 115
Lockhart D, 318 Nesheim S, 192 Ramalingam S, 573
Loomis-Price LD, 9 Ni A, 131 Ranjan A, 115, 572
L6pez-Cortés LF, 240 Nkoumou MO, 345 Ratto-Kim S, 9
Loughran TP, 406 Nuesch R, 570 Rawal BD, 551
Luketic VA, 30 Nujfiez M, 465 Razak MH, 311
Lungren JD, 452 Nyland SB, 406 Recchia O, 424
Lutalo T, 446 Reiss P, 514
O’Brien TR, 70 Renzullo PO, 215
O’Shaughnessy MV, 2, 522 Rey E, 112
Mahanontharit A. 375 O'Sullivan MJ, 170 Rezza G, 424
Major C, 534 Odhiambo J, 223 Ribera J-M, 347
Mandalia S, 238 Oleske JM, 353 Rinehart AR, 268
Manor E, 477 Ompad DC, 86 Rios P, 465
Manzoni P, 482 Ono-Kihara M, S55 Ripamonti D, 259
Maradona JA, 348 Oriol A, 347 Ristig MB, 153
Marasco WA, 245 Osame M, 328 Robison E, 298
Mariner WK, 117 Rodriguez-Guardado A, 348
Maserati R, 268 Pachon J, 240 Rojanawiwat A, 157
Massi M, 424 Paganelli R, 464 Rompalo AM, 203
Mata R, 240 Palepu A, 522 Rosenberg HM, 62
Maupin R, 170 Palumbo P, 192 Rosenberg PS, 70
MaWhinney S, 469 Pandey K, 115 Ross D, 351
Mazzotta F, 268 Parker MM, 292 Rossini A, 318
Mbulaiteye SM, 527 Pathipvanich P, 157 Rouzioux C, 112
McDonald A, S18 Paul S, 494 Ruiz-Valderas R, 240
McKenna MT, 62 Pellet P, 335 Rutherford G, 551
McNaghten AD, 499 Peng L, 124 Ruxrungtham K, 375, 570
McNeil JG, 215 Penner J, 223
Meier AS, 223 Pérez-Olmeda M, 465 Saengwonloey O, S63
Merrill D, 143 Perman MI, 104 Sajja P, 399
Metzger DS, 161 Perrin L, 542 Salomén HE, 441
Meyer L, 335 Peterson KE, 560 Sanne I, 18
Middleton T, 57 Peyramond D, 38 Sanyal AJ, 30
Miedema FA, 514 Pezzotti P, 424 Sateren WB, 215
Milla F, 347 Phanuphak P, 375, 570 Sawanpanyalert P, 157
Mills AS, 30 Phillips AN, 452 Schechter M, 435
Millson M, 534 Phillips KA, 182 Schechter MT, 2
Minkoff H, 210, 298 Pierotti P, 268 Schiavone C, 464
Moatti J-P, 38 Piessens E, 298 Schlossberg J, 534
Mofenson LM, 170 Piliero P, 18 Schneider L, 482
Mollnes TE, 354 Pinti M, 370 Schnittman S, 18
Monhaphol T, 375 Pisani E, S3 Schock B, 281
Monsuez J-J, 490 Pizarro M, 441 Schuitemaker H, 514
Montaner JSG, 522 Pizzigallo E, 464 Schuman P, 203
Montella F, 424 Poggi C, 462 Schwartlinder B, S3
Moore AL, 452 Pollack LM, 417 Sciandra M, 424
Moorman AC, 48 Pons G, 112 Seage GR III, 161
Mora S, 482 Pozniak AL, 238 Selik RM, 62
Morgado MG, 338 Prabu K, 573 SEROCO Study Group, 335
Morlese JF, 238 Puca A, 441 Serwadda D, 446
Morris M, 196 Puoti M, 259 Sewankambo NK, 446
Msamanga G, 560 Purdue L, 281 Seyfried W, 153
Muchina B, 223 Putzolu V, 259 Shafer KP, 551
Murakami A, 245 Shapiro DE, 170
Mwachari C, 223 Qazi NA, 238 Sheon AR, 161
Myers L, 281 Qiu Y, 124 Shi M, 124
Myers T, 534 Quartier P, 112 Shiffman ML, 30
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
AUTHOR INDEX
Shikuma C, 370 Taylor J, 292 Wabwire-Mangen F, 446
Shikuma CM, 281 Tebas P, 153 Wade N, 292
Shikuma KM, 370 Teeratakulpisarn S, 570 Walker N, S3
Shiramizu B, 370 Telgt D, 135 Wallace E, 534
Siangphoe U, 570 Testolin C, 482 Wallis RS, 281
Sill AM, 94 Thakur CP, 572 Wang B, 124
Simon A, 490 The European Collaborative Study, 380 Wang F-S, 124
Sinha PK, 115 Théodorou I, 335 Wang Z, 124
Sinicco A, 424 Thiry A, 18 Warachit P, 157
Sinkala M, 506 Tinelli C, 268 Ward DJ, 48
Small W, 2 Todd J, 351 Ward MA, 388
Smith E, $33 Tomasoni L, 259 Wawer MJ, 446
Smith H, 94 Torti C, 259, 268 Weber K, 298
Snyder S, 281 Travasi F, 464 White AC Jr, 399
Solas C, 462 Treluyer JM, 112 Williams C, 9
Soriano V, 465 Tural C, 347 Williamson C, 153
Sperling RS, 170 Tyndall M, 522 Williamson JM, 203
Spiegelman D, 560 Tyndall MW, 2 Wilson MS, 30
Spielberg F, 318 Winkler C, 124
Spinetti A, 259 Ueland T, 354 Wohlfeiler D, 417
Spire B, 38 Ugen KE, 406 Wongchoosie S, 157
Spittal PM, 2 ul Hassan S, 394 Wood E, 2
Spritzler J, 281 Ungsedhaphand C, 570 Wood KC, 48
Squires K, 18 Usuku K, 328 Wood RW, 318
Srasuebkul P, 570 Woods WJ, 417
Sridharan G, 573 van Heeswijk RP, 375
Stall RD, 417 van Rossum AMC, 135 Xu D-P, 124
Sterling RK, 30 Vanhems P, 542
Stern LD, 104 Vanzulli A, 482 Yamamoto T, $55
Stout JP, 506 Veber F, 112 Yan P, S24
Strathdee SA, 86, 229, 394, 429 Vecchiet J, 464 Yang G, 13]
Stravitz RT, 30 Verma N, 115 Ye J-J, 124
Stricker BCH, 135 Vermund SH, 506 Yingseree P, 157
Stringer JSA, 506 Viciana P, 240 Yip B, 522
Sturkenboom MCJM, 135 Vigan A, 482 Yoshitke K, 157
Sucupira MC, 551 Vijayakumar TS, 573
Sui J, 245 Villamor E, 560 Zafar T, 394
Suligoi B, 424 Vink P, 192 Zaltron S, 259
Sullivan K, 192 Visnegarwala F, 399 Zanini B, 259
Sullivan T, 292 Vittecog D, 490 Zhang B, 124
Sutherland D, $24 Vizzard J, 542 Zhang D, 245
Sutherland J, $24 Vlahov D, 86, 229, 429 Zietse R, 135
Swiss HIV Cohort Study, 542 Vogel R, 388 Zingariello P, 464
Szezech LA, 203 Voirin N, 542 Zorrilla CD, 170
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
JAIDS Journal of Acquired Immune Deficiency Syndromes
32:580-589 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia
Journal of Acquired Immune Deficiency Syndromes
Volume 32, 2003
Subject Index
Abnormalities, in uninfected children exposed to antiretrovi- markers and cofactors in predicting, 514
ral therapy in utero or early life, 380 psychological distress and in injection drug users, 429
Acute retroviral syndrome, incubation and duration of symp- AIDS-related lymphoma, improved outcome of with viro-
toms of as independent predictors of AIDS progres- logic response to HAART (letter), 347
sion, 542 AIDS-related opportunistic infections, risk factors for among
Adherence urban-dwelling HIV-infected women, 223
to antiretroviral therapy and HIV RNA persistence in se- Alanine aminotransferase flares, in combination antiretroviral
men, 435 therapy, 259
to highly active antiretroviral therapy in urban clinic pa- Allele frequencies, in Chinese ethnic groups, 124
tients, 399 ALVAC-HIV (vCP205) immunization, env-specific T-cell
Adipose tissue, intra-abdominal, with increased exposure to epitopic responses with, 9
highly active antiretroviral therapy in HIV-infected Amniocytes, phosphorylation of 3'-azidothymidine in, 477
children, 482 Anti-HIV agents, impaired virologic response to with ongo-
Adolescents ing injection drug use, 522
applying for military service, HIV-1 infection among, 215 Anti-HIV immunotherapy, macaque primary CD4-enriched
peripheral blood mononuclear cell activation in, 245
HIV-1! infection risk to in rural Uganda, 446
Antibody avidity, in identifying recent HIV infections, 424
social circumstances of injection drug use initiation in
Antiretroviral drugs
shooting galleries, 86
measurement of by interlaboratory quality control pro-
trends in AIDS cases in, S68
gram, 287
Afghanistan, HIV knowledge and risk behaviors among drug
survival benefit from in resource-constrained setting, 157
users in, 394
Antiretroviral-naive population, nonnucleoside reverse tran-
Africa
scriptase inhibitor resistance among, 153
age differences in sexual partners and HIV-1 risk in, 446
Antiretroviral therapy
meningitis in HIV-positive versus -negative patients in
adherence to and HIV RNA persistence in semen, 435
(letter), 345
carotid intima-media thickness and, 490
risk factors for pneumonia among urban-dwelling HIV-
cessation of prophylactic use of in reducing vertical trans-
infected women in, 223
mission, 170
sexual transmission of HIV in (letter), 349, 351
combination, efficacy and treatment-limiting toxicity of in
Age, HIV-1 infection risk and in rural Uganda, 446 treatment-experience patients, 494
AIDS case reporting, S1 differences in prescription of in HIV-infected patients, 499
in Australia, $18 in utero or early life exposure to, 380
in Canada, $24 limited evolution of resistance-associated mutations of, 57
in Denmark, $33 lipoatrophy incidence and risk factors with, 48
in Europe, S39 pharmacokinetics and efficacy of saquinavir-sgc, low-dose
in Germany, S49 ritonavir and efavirenz after (letter), 240
in Japan, $55 severe hepatotoxicity of, 259
surveillance systems in, $3 strategies perinatal HIV transmission prevention with in
in Thailand, S63 high-prevalence, resource-poor settings, 506
in United States, S68 variables in lipodystrophy response to, 104
AIDS cases, definition of, S68 viral load and in children (letter), 112
AIDS epidemic Antiretroviral therapy-naive seroconverters, short-term CD4
gay bathhouses in, 417 cell response after HAART initiation in, 303
in India (letter), 573 Apoptosis, prednisone effects on, 281
AIDS incidence, trends in, S68 Appointment adherence, use of highly active antiretroviral
AIDS progression therapy and, 399
immune deficiency and risk for malignancy with, 527 Argentina, cluster of human T-cell lymphotropic virus type
incubation and duration of symptoms at acute retroviral I-associated myelopathy/tropical spastic paraparesis
syndrome and, 542 in, 441
SUBJECT INDEX 581
Asia Cancer, immune deficiency and risk for among AIDS pa-
HIV/AIDS surveillance in, $63 tients, 527
HIV knowledge and risk factors among men who have sex Carotid arteries, thickness of in heavily pretreated HIV-in-
with men in, 80 fected patients, 490
pharmacokinetics of saquinavir with ritonavir in HIV-1- Case surveillance
infected subjects in, 375 in Australia, $18
survival benefit from non-highly active antiretroviral in Canada, $24
therapy in, 157 in Denmark, $33
At-risk populations in Europe, $39
defining, S3 in Germany, S49
informed consent process for in HIV vaccine efficacy tri- in Japan, S55
als, 161 in United States, S68
Atazanavir, phase 2 clinical trial of with didanosine and CCR2 allele frequencies, in Chinese populations, 124
stavudine, 18 CCRS allele frequencies, in Chinese populations, 124
Attitudes, in voluntary HIV testing among inmates, 534 CCRS5-A32 heterozygosity, in risk of perinatal HIV-1 infec-
Australia, HIV/AIDS surveillance systems in, $18 tion, 70
Automated enzyme immunoassay, in identifying recent HIV CCRS gene
infections, 424
32-base pair deletion distribution of in Chinese minorities,
Avidity index, in identifying recent HIV infections, 424 131
AxSYM, in identifying recent HIV infections, 424 expression of in Chinese minorities, 13]
Azidothymidine, phosphorylation of in maternal and fetal CD4 cells
peripheral blood mononuclear cells during gestation count of
and at term, 477 gender and in response to highly active antiretroviral
therapy, 452
and risk for malignancy among AIDS patients, 527
B/F recombinant virus, in Venezuela, 338 counts of
Bacterial meningitis, in HIV-positive versus -negative pa- prednisone effects on, 281
tients (letter), 345 optimization of ex vivo activation and expansion of, 245
Baseline model, for predicting residual time to AIDS and short-term response of after HAART initiated from sero-
death, 514 conversion, 303
Bathhouses, public policy regulating, 417 CD8* cells, HIV-1-producing cells and in human lymphoid
Behavior change, CDC guidelines for, 182 tissue, 469
Behavioral methodologies, versus behavioral surveillance, Cell-mediated immunity, with undetectable viral load on pro-
$12 tease inhibitor- versus non-protease inhibitor-based
Behavioral risk, in voluntary HIV testing among inmates, highly active antiretroviral therapy (letter), 570
534 Cell proliferation, of macaque primary CD4-enriched periph-
Behavioral surveiliance, S1 eral blood mononuclear cell, 245
in Australia, $18 Centers for Disease Control, HIV counseling and testing
in Canada, $24 guidelines of, 182
in catalyzing action, $12 Chemokines, in HIV-1 disease progression, 335
in Denmark, $33 Children
in Germany, S49 AIDS trends in, S68
in Japan, S55 antiretroviral drug plasma concentrations and viral load in
in Thailand, S63 (letter), 112
in United States, S68 exposed to antiretroviral therapy in utero or in early life,
Behavioral surveys, repeated, S3 380
Biological surveillance data, in evaluating response, S3 increased lipodystrophy with exposure to highly active
Blood donors antiretroviral therapy in, 482
HIV surveillance among in Europe, $39 zidovudine prophylaxis for AIDS in, 170
HTLV-I-related clinical and laboratory findings in, 328 Chimpanzees, zoonotic cross-species transmission of SIVs
Blood HIV-1 RNA levels, with resistance to lopinavir (let- from, 362
ter), 462 China, CCR5 gene 32-base pair deletion and CCR5 expres-
Burma, assessing magnitude of HIV/AIDS epidemic in, 311 sion in minorities in, 131
Chinese populations
CCRS gene 32-base pair deletion and CCRS5 expression in,
C-reactive protein 131
in HIV disease progression, 354 surveys of allele frequencies in, 124
as mortality predictor in HIV-1-infected women, 210 Clinical progression, gender and in highly active antiretrovi-
Canada ral therapy, 452
combining data sources in monitoring HIV epidemic in, Clinical trials
$24 phase 2, of atazanavir with didanosine and stavudine, 18
voluntary HIV testing among inmates in, 534 of prednisone, 281
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
582 SUBJECT INDEX
Cofactors, in predicting residual time to AIDS and death, gender and in highly active antiretroviral therapy, 452
514 incubation and duration of symptoms at acute retroviral
Coinfection syndrome and, 542
clinical spectrum of hepatitis C virus in, 30 mannose-binding lectin and, 354
of kala-azar in India (letter), 572 markers and cofactors in predicting, 514
modulation of HIV infection and type | cytokine expres- psychological distress and in injection drug users, 429
sion in, 406 zidovudine prophylaxis to prevent, effect of cessation of
of visceral leishmaniasis (letter), 115 during pregnancy, 170
Combination drug therapy Drug interactions, of saquinavir with ritonavir in HIV-1-in-
efficacy and treatment-limiting toxicity of in treatment- fected subjects, 375
experienced patients, 494 Drug resistance
severe hepatotoxicity of, 259 among antiretroviral-naive HIV-positive pregnant women,
Community, safer injection facilities impact on, 2 153
Complement, in HIV disease progression, 354 HIV-1 RNA levels and in semen versus blood with lopina-
Consistency analysis, of variables in lipodystrophy syndrome, vir-containing regimen (letter), 462
104 limited evolution of mutations in testing for, 57
Cord blood mitochondrial DNA toxicity, in HIV-infected prevalence of among HIV-infected newborns, 292
women receiving nucleoside reverse transcriptase in- with real versus virtual phenotype, 268
hibitors during pregnancy, 370 Drug use, factors in readiness to stop, 229
Coreceptors Dual energy x-ray absorptiometry (DEXA), in analysis of
in Chinese populations, 124 lipodystrophy syndrome, 104
macaque primary CD4-enriched peripheral blood mono- Dual therapy, survival benefit from in resource-constrained
nuclear cell, 245 setting, 157
Corticosteroids, in T-cell loss in AIDS, 281 Dyslipidemia, with atazanavir with didanosine and stavudine,
Counseling preferences, overcoming barriers to, 318 18
Creatinine serum levels, in mortality in HIV-infected women,
203
CREST study, on antiretroviral therapy resistance-associated Early detection
mutations, 57 medical encounters before HIV-1 diagnosis in, 14 3
Cross-species transmission, multiple lineages of SIVs in, 362 strategies for HIV testing in, 318
CX3CRI genotypes, deleterious genetic influence of on Eastern Europe, HIV/AIDS surveillance in, $39
HIV-1 disease progression, 335 Editorials
Cytokines, type 1, modulation of expression parameters of by JAIDS at 15: meeting the challenge, |
morphine during in vitro HTLV-I and HIV-1 coinfec- Long-term outcomes in infants born to HIV-infected
tion, 406 women, 353
Cytotoxic T lymphocytes, HIV-1-producing in human lym- Protease inhibitor-associated diabetes mellitus: a potential
phoid tissue, 469
cause of morbidity and mortality, 243
Taking informed consent seriously in global HIV vaccine
Data sources, in HIV epidemic monitoring in Canada, $24 research, 117
Death, causes of, changing rules for selecting, 62 Efavirenz, pharmacokinetics and efficacy of in patients with
Death certificates, changing rules for underlying causes in, prior antiretroviral therapy (letter), 240
62 Efficacy
Demographic variables, in HIV-1 infection prevalence among of atazanavir with didanosine and stavudine, 18
military service applicants, 215 cell type and, 255
Denmark, HIV/AIDS surveillance in, $33 of lopinavir in individuals experiencing protease inhibitor
Developed countries, AIDS surveillance in, S1 failure (letter), 238
Developing countries of saquinavir-sgc, low-dose ritonavir and efavirenz after
AIDS surveillance in, S1 antiretroviral therapy (letter), 240
survival benefit from non-highly active antiretroviral Emtricitabine, cell type and anti-HIV-1 efficacy of, 255
therapy in, 157 Endocrine function, with protease inhibitor use in HIV-in-
Diabetes mellitus fected women, 298
protease inhibitor-associated (editorial), 243 Env-specific T-cell epitopic responses, in HIV-1-infected and
protease inhibitor use and among HIV-infected women, -uninfected adults, 9
298 Epidemic monitoring
Diagnosis combining data sources in, S24
medical encounters before, 143 in Japan, S55
quantitative RNA testing of infants in, 192 Epidemic trends
Diagnostic tests, in identifying recent HIV infections, 424 interpreting data in, S3
Didanosine, with atazanavir, phase 2 clinical trial with, 18 monitoring of, S1
Disease progression Epidemics
deleterious genetic influence of CX3CR1 genotypes on, assessing magnitude of in Burma, 311
335 concentrated, $3
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
SUBJECT INDEX 583
generalized, S3 Genotipo-Fenotipo di Resistenza (GenPheRex) trial, follow-
surveillance systems for, S3 up of, 268
Epidemiology Genotype
of AIDS in Germany, S49 of Chinese minorities, 131
of CCRS gene 32-base pair deletion and CCRS5 expression in nonnucleoside reverse transcriptase inhibitor resistance
in Chinese minorities, 131 among HIV-positive pregnant women, 153
of clients mobile health vans and traditional STD clinics, Genotypic resistance
388 prevalence of among HIV-infected newborns, 292
of HIV-1 infection to zidovudine prophylaxis to reduce vertical transmission,
among U.S. military personnel, 215 170
in Venezuela, 338 Geographic diversity, of HIV-1 infection prevalence among
of immune deficiency and risk for malignancy in AIDS, military service applicants, 215
a2) Germany, HIV/AIDS surveillance in, $49
of progression to AIDS in injection drug users, 429 Gestation, phosphorylation of 3’-azidothymidine in maternal
of protease inhibitor use and diabetes mellitus in HIV- and fetal PBMCs during, 477
infected women, 298
proteinuria and elevated serum creatinine levels in, 203
of risk behaviors in mentally ill, 77 Harm reduction, safer injection facilities in, 2
Erratum: “Current situation and regional perspective on HDL cholesterol, increased intra-media thickness and, 490
HIV/AIDS surveillance in Europe” Hamers et al. Health department contact, in partner notification, 196
(2003;32(suppl 1):S39-S48), 467 Health-related quality of life, after highly active antiretroviral
Ethics therapy, 38
of informed consent in AIDS vaccine research (editorial), Health surveys, of prevalence of HIV risk behaviors, risk
117 perceptions, and testing among mentally ill, 77
in new CDC guidelines for HIV counseling and testing, Hepatitis C virus
182 clinical spectrum of in HIV coinfection, 30
Ethnic groups genotypes of in treatment failure for hepatitis C virus in
CCRS gene 32-base pair deletion and CCRS5 expression in, HIV-positive drug users (letter), 465
131 with HIV infection and lipodystrophy (letter), 348
surveys of allele frequencies in, 124 treatment failure for in HIV-positive drug users (letter),
use of highly active antiretroviral therapy among, 399 465
Europe Hepatotoxicity, of combination antiretroviral treatment, 259
AID surveillance in, SI Heroin users, HIV knowledge and risk behaviors among in
current situation and regional perspectives on HIV/AIDS Afghanistan and Pakistan, 394
surveillance in, $39 Heteroduplex mobility assay, of HIV-1 subtypes in Venezu-
uninfected children exposed to antiretroviral therapy in ela, 338
utero or early life in, 380 High-prevalence, resource-poor setting, strategies for admin-
istering nevirapine to prevent perinatal HIV transmis-
sion in, 506
High-risk behavior
Fat loss, abnormal, incidence and risk factors for in ambula-
accessing populations with, $3
tory HIV-1-infected patients, 48
informed consent process for in HIV vaccine efficacy
Fetal peripheral blood mononuclear cells, phosphorylation of
trials, 161
3’-azidothymidine in during gestation and at term,
Highly active antiretroviral therapy
477
effectiveness of, S39
factors associated with in new urban clinic patients, 399
gender and virologic, immunologic, and clinical response
Gabon, meningitis in HIV-positive versus -negative patients to, 452
in (letter), 345 health-related quality of life after, 38
Gay bathhouses, public policy regulating, 417 increased lipodystrophy with exposure to in HIV-infected
Gay men children, 482
HIV knowledge and risk factors among in Vietnam, 80 lipoatrophy incidence and risk factors with, 48
HIV treatments optimism among, 545 lipodystrophy syndrome with, 104
new strategies among clients of sex venues for, 318 mannose-binding lectin in disease progression and, 354
public policy regulating risk behaviors of in bathhouses, phase 2 clinical trials of in antiretroviral-naive subjects, 18
417 prescription differences for in large cohort of HIV-infected
Gelatin capsules, hard and soft, pharmacokinetics of, 375 patients, 499
Gender, virologic, immunologic, and clinical response to protease inhibitor-based versus non-protease inhibitor
highly active antiretroviral therapy and, 452 based (letter), 570
Gene therapy strategies, macaque primary CD4-enriched pe- real versus virtual phenotype guiding, 268
ripheral blood mononuclear cell activation in, 245 short-term CD4 cell response after, 303
Genetics, in HIV-1! disease progression, 335 virologic response to
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003
584 SUBJECT INDEX
impaired with ongoing injection drug use, 522 among pregnant women from Tanzania, 560
improved outcome of AIDS-related lymphoma with (let- hepatitis C virus and lipodystrophy with (letter), 348
ter), 347 increased mortality rate from, 62
Histology, with combination antiretroviral therapy, 259 HIV knowledge, risk factors and among men who have sex
HIV-1 infection with men in Vietnam, 80
among U.S. military service applicants, 215 HIV optimism, among gay men, 545
C-reactive protein as mortality predictor in, 210 HIV risk, age differences in sexual partners and in rural
env-specific T-cell epitopic responses to ALVAC-HIV Uganda, 446
(vCP205) immunization in, 9 HIV serosurveillance, in Europe, $39
modulation of by morphine during in vitro HTLV-I and HIV testing
HIV-1 coinfection, 406 anonymous clients in Santos, Brazil, 551
perinatal, CCR5-A32 heterozygosity in risk of, 70 HIV risk behaviors and risk perceptions and in mentally
ill, 77
RNA levels of, resistance and drug diffusion with in se-
men versus blood during lopinavir regimen (letter), new CDC guidelines on, 182
462 overcoming barriers to, 318
two-stage sensitive/less-sensitive test strategy in classifica- patterns of, S39
tion of, 94 in surveillance systems in Australia, $18
HIV-1-producing cells, CD8* cells and in human lymphoid voluntary, among inmates, 534
tissue, 469 HIV vaccine
HIV-1 risk groups, allele frequencies in among Chinese, 124 informed consent in research on (editorial), 117
HIV-2 sub-epidemic, in tertiary care center in south India prototype informed consent process for efficacy trials of,
(letter), 573 161
HIV-1 subtypes, in Venezuela, 338 Homosexual men. See Gay men
HIV-1-uninfected adults, env-specific T-cell epitopic re- Human T-cell leukemia virus type I, modulation of during in
sponses in, 9 vitro coinfection with HIV-1, 406
HIV/AIDS epidemic, assessing magnitude of in Burma, 311 Human T-cell lymphotropic virus type | (HTLV-D
HIV/AIDS programs clinical and laboratory findings for blood donors with, 328
effectiveness of, S49 myelopathy/tropical spastic paraparesis associated with,
monitoring effectiveness of, $55 cluster of in Argentina, 441
in Thailand, S63 preclinical symptoms of, 328
HIV/AIDS research, challenge of (editorial), | subgroups of, 328
HIV/AIDS surveillance
in Australia, S18
challenges of, S3 Immune deficiency, among AIDS patients, 527
in Denmark, $33 Immune reconstitution, with combination antiretroviral
design and implementation of, S12 therapy, 259
in Europe, $39 Immune response
in Germany, S49 after HAART in seroconverters, 303
global perspective on, S3 with undetectable viral load on protease inhibitor- versus
in Japan, S55 non-protease inhibitor-based highly active antiretrovi-
in new era, S] ral therapy (letter), 570
purposes of, S3 Immunoassays, in identifying recent HIV infections, 424
second generation, S3 Immunology
in Thailand, S63 gender and in response to highly active antiretroviral
in United States, S68 therapy, 452
HIV case reporting of prednisone with CD4 cell counts of 200-700 mm, 281
in Canada, $24 Immunotherapy, macaque primary CD4-enriched peripheral
in Denmark, $33 blood mononuclear cell activation in, 245
in Europe, $39 Incidence
in Germany, S49 avidity index and automated enzyme immunoassay in de-
in Japan, S55 termining, 424
partner notification in, 196 in Denmark, $33
in United States, S68 India
HIV coinfection HIV-2 sub-epidemic in (letter), 573
clinical spectrum of hepatitis C virus in, 30 kala-azar coinfection with HIV in (letter), 572
of visceral leishmaniasis (letter), 115 visceral leishmaniasis and HIV coinfection in (letter), 115
HIV counseling, testing, referral (CTR) services Indinavir, persistent leukocyturia and loss of renal function
new CDC guidelines on, 182 with, 135
in traditional STD clinics versus mobile health vans, 388 Infants
HIV drug resistance, with real versus virtual phenotype, 268 of HIV-infected women, long-term outcomes in (editorial),
HIV infection 353
among adolescent and young adult injection drug users, 86 quantitative RNA testing in HIV diagnosis of, 192
JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 32, No. 5, April 15, 2003